Mirati Therapeutics, Inc. (MRTX) |
|
37.18 0.49 (1.34%)
|
03-31 16:00 |
|
Open: |
36.8 |
Pre. Close: |
36.69 |
|
High:
|
37.89 |
Low:
|
36.22 |
|
Volume:
|
1,176,109 |
Market Cap:
|
2,227(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:20:35 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 50.1 One year: 54.95 |
| Support: |
Support1: 36.16 Support2: 30.09 |
| Resistance: |
Resistance1: 42.89 Resistance2: 47.04 |
| Pivot: |
39.68  |
| Moving Average: |
MA(5): 37.13 MA(20): 40.01
MA(100): 51.94 MA(250): 61.42 |
| MACD: |
MACD(12,26): -2.3 Signal(9): -2.1 |
| Stochastic oscillator: |
%K(14,3): 10.2 %D(3): 8.7 |
| RSI: |
RSI(14): 35.5 |
| 52-week: |
High: 101.3 Low: 32.95 |
| Average Vol(K): |
3-Month: 1,151 (K) 10-Days: 918 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MRTX ] has closed above bottom band by 23.6%. Bollinger Bands are 58.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
37.92 - 38.19 |
38.19 - 38.4 |
|
Low:
|
35.73 - 36.01 |
36.01 - 36.22 |
|
Close:
|
36.81 - 37.25 |
37.25 - 37.58 |
|
Company Description |
|
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. |
Headline News |
Thu, 30 Mar 2023
Mirati (MRTX) Down 16.1% Since Last Earnings Report: Can It ... - Nasdaq
Tue, 28 Mar 2023
Is Mirati Therapeutics Inc (MRTX) a Leader in the Biotechnology Industry? - InvestorsObserver
Fri, 24 Mar 2023
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares Purchased by ... - MarketBeat
Wed, 22 Mar 2023
Is Mirati Therapeutics Inc (MRTX) a Stock to Watch After Losing -7.71% This Week? - InvestorsObserver
Thu, 16 Mar 2023
Guru Fundamental Report for MRTX - Benjamin Graham - Nasdaq
Thu, 16 Mar 2023
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Given Consensus Rating ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
58 (M) |
|
% Held by Insiders
|
4.32e+007 (%) |
|
% Held by Institutions
|
1.5 (%) |
|
Shares Short
|
9,880 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-7.4234e+008 |
|
EPS Est Next Qtl
|
-0.86 |
|
EPS Est This Year
|
-3.21 |
|
EPS Est Next Year
|
-2.77 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-6 |
|
Return on Assets (ttm)
|
312.5 |
|
Return on Equity (ttm)
|
-36.5 |
|
Qtrly Rev. Growth
|
1.18e+007 |
|
Gross Profit (p.s.)
|
-92.41 |
|
Sales Per Share
|
-66.7 |
|
EBITDA (p.s.)
|
-3.6801e+008 |
|
Qtrly Earnings Growth
|
-8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-580 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.56 |
|
Price to Cash Flow
|
1.37 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
1.063e+007 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
